Search

Your search keyword '"Perales, Miguel-Angel"' showing total 382 results
Start Over Author "Perales, Miguel-Angel" Journal transplantation and cellular therapy
382 results on '"Perales, Miguel-Angel"'

2. Shift from Widespread to Tailored Antifungal Prophylaxis in Lymphoma Patients Treated with CD19 CAR T Cell Therapy: Results from a Large Retrospective Cohort

Author

Melica, Giovanna, Luna de Abia, Alejandro, Shah, Gunjan L., Devlin, Sean, Corona, Magdalena, Fein, Joshua, Dahi, Parastoo B., Giralt, Sergio A., Lin, Richard J., Palomba, M. Lia, Parascondola, Allison, Park, Jae, Salles, Gilles, Saldia, Amethyst, Scordo, Michael, Shouval, Roni, Perales, Miguel-Angel, and Seo, Susan K.

Published
2025
Full Text
View/download PDF

3. Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical Trial.

Author

Shaw, Bronwen, Jimenez-Jimenez, Antonio, Burns, Linda, Logan, Brent, Khimani, Farhad, Shaffer, Brian, Shah, Nirav, Mussetter, Alisha, Tang, Xiao-Ying, McCarty, John, Alavi, Asif, Farhadfar, Nosha, Jamieson, Katarzyna, Hardy, Nancy, Choe, Hannah, Ambinder, Richard, Anasetti, Claudio, Perales, Miguel-Angel, Spellman, Stephen, Howard, Alan, Luznik, Leo, Norkin, Maxim, Pidala, Joseph, Ratanatharathorn, Voravit, Confer, Dennis, Devine, Steven, Horowitz, Mary, Bolaños-Meade, Javier, and Komanduri, Krishna

Subjects
HLA, Hematopoietic cell transplant, Mismatched unrelated donor, Post transplant cyclophosphamide, Humans, Bone Marrow, Follow-Up Studies, Prospective Studies, Cyclophosphamide, Graft vs Host Disease, Unrelated Donors, Recurrence
Abstract

The use of post-transplantation cyclophosphamide (PTCy) as graft-versus-host disease (GVHD) prophylaxis has resulted in reductions in GVHD and improved outcomes in allogeneic hematopoietic cell transplantation (HCT) using HLA-mismatched related donors. We report the 3-year outcomes of the first multicenter prospective clinical trial using PTCy in the setting of mismatched unrelated donor (MMUD) bone marrow HCT. The study enrolled 80 patients, treated with either myeloablative conditioning (MAC; n = 40) or reduced-intensity conditioning (RIC; n = 40), with the primary endpoint of 1-year overall survival (OS). The median follow-up for this study was 34 months (range, 12 to 46 months) in the RIC group and 36 months (range, 18 to 49 months) in the MAC group. Three-year OS and nonrelapse mortality were 70% and 15%, respectively, in the RIC group and 62% and 10% in the MAC group. No GVHD was reported after 1 year. The incidence of relapse was 29% in the RIC group and 51% in the MAC group. OS did not differ based on HLA match grade (63% in the 7/8 strata and 71% in the 4 to 6/8 strata). These encouraging outcomes, which were sustained for 3 years post-HCT, support the continued exploration of MMUD HCT using a PTCy platform. Important future areas to address include relapse reduction and furthering our understanding of optimal donor selection based on HLA and non-HLA factors.

Published
2023

4. Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis.

Author

Saliba, Rima, Alousi, Amin, Pidala, Joseph, Arora, Mukta, Spellman, Stephen, Hemmer, Michael, Wang, Tao, Abboud, Camille, Ahmed, Sairah, Antin, Joseph, Beitinjaneh, Amer, Buchbinder, David, Byrne, Michael, Cahn, Jean-Yves, Choe, Hannah, Hanna, Rabi, Hematti, Peiman, Kamble, Rammurti, Kitko, Carrie, Laughlin, Mary, Lekakis, Lazaros, MacMillan, Margaret, Martino, Rodrigo, Mehta, Parinda, Nishihori, Taiga, Patel, Sagar, Perales, Miguel-Angel, Rangarajan, Hemalatha, Ringdén, Olov, Rosenthal, Joseph, Savani, Bipin, Schultz, Kirk, Seo, Sachiko, Teshima, Takanori, van der Poel, Marjolein, Verdonck, Leo, Weisdorf, Daniel, Wirk, Baldeep, Yared, Jean, Schriber, Jeffrey, Champlin, Richard, and Ciurea, Stefan

Subjects
Graft-versus-host disease, Non-relapse mortality, Post-transplantation cyclophosphamide, Prophylaxis, Antilymphocyte Serum, Cyclophosphamide, Female, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Male, Retrospective Studies
Abstract

Post-transplantation cyclophosphamide (PTCy) has been shown to effectively control graft-versus-host disease (GvHD) in haploidentical (Haplo) transplantations. In this retrospective registry study, we compared GvHD organ distribution, severity, and outcomes in patients with GvHD occurring after Haplo transplantation with PTCy GvHD prophylaxis (Haplo/PTCy) versus HLA-matched unrelated donor transplantation with conventional prophylaxis (MUD/conventional). We evaluated 2 cohorts: patients with grade 2 to 4 acute GvHD (aGvHD) including 264 and 1163 recipients of Haplo and MUD transplants; and patients with any chronic GvHD (cGvHD) including 206 and 1018 recipients of Haplo and MUD transplants, respectively. In comparison with MUD/conventional transplantation ± antithymocyte globulin (ATG), grade 3-4 aGvHD (28% versus 39%, P = .001), stage 3-4 lower gastrointestinal (GI) tract aGvHD (14% versus 21%, P = .01), and chronic GI GvHD (21% versus 31%, P = .006) were less common after Haplo/PTCy transplantation. In patients with grade 2-4 aGvHD, cGvHD rate after Haplo/PTCY was also lower (hazard ratio [HR] = .4, P < .001) in comparison with MUD/conventional transplantation without ATG in the nonmyeloablative conditioning setting. Irrespective of the use of ATG, non-relapse mortality rate was lower (HR = .6, P = .01) after Haplo/PTCy transplantation, except for transplants that were from a female donor into a male recipient. In patients with cGvHD, irrespective of ATG use, Haplo/PTCy transplantation had lower non-relapse mortality rates (HR = .6, P = .04). Mortality rate was higher (HR = 1.6, P = .03) during, but not after (HR = .9, P = .6) the first 6 months after cGvHD diagnosis. Our results suggest that PTCy-based GvHD prophylaxis mitigates the development of GI GvHD and may translate into lower GvHD-related non-relapse mortality rate.

Published
2022

5. Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With Lymphoma

Author

Lorenc, Rachel, Shouval, Roni, Flynn, Jessica R., Devlin, Sean M., Saldia, Amethyst, De Abia, Alejandro Luna, De Lapuerta, Magdalena Corona, Tomas, Ana Alarcon, Cassanello, Giulio, Leslie, Lori A., Rejeski, Kai, Lin, Richard J., Scordo, Michael, Shah, Gunjan L., Palomba, M. Lia, Salles, Gilles, Park, Jae, Giralt, Sergio A., Perales, Miguel-Angel, Ip, Andrew, and Dahi, Parastoo B.

Published
2024
Full Text
View/download PDF

7. Post-Transplantation Cyclophosphamide Is Associated with an Increase in Non-Cytomegalovirus Herpesvirus Infections in Patients with Acute Leukemia and Myelodysplastic Syndrome

Author

Singh, Anurag, Dandoy, Christopher E, Chen, Min, Kim, Soyoung, Mulroney, Carolyn M, Kharfan-Dabaja, Mohamed A, Ganguly, Siddhartha, Maziarz, Richard T, Kanakry, Christopher G, Kanakry, Jennifer A, Patel, Sagar S, Hill, Joshua A, De Oliveir, Satiro, Taplitz, Randy, Hematti, Peiman, Lazarus, Hillard M, Abid, Muhammad Bilal, Goldsmith, Scott R, Romee, Rizwan, Komanduri, Krishna V, Badawy, Sherif M, Friend, Brian D, Beitinjaneh, Amer, Politikos, Ioannis, Perales, Miguel-Angel, and Riches, Marcie

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Immunology, Rare Diseases, Cancer, Clinical Research, Stem Cell Research - Nonembryonic - Human, Hematology, Stem Cell Research, Transplantation, Infectious Diseases, Infection, Inflammatory and immune system, Good Health and Well Being, Cyclophosphamide, Cytomegalovirus Infections, Herpesviridae, Humans, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Prospective Studies, Non-CMV herpesvirus, Post-transplantation, cyclophosphamide, Haploidentical, Epstein-Barr virus, HHV-6, Post-transplantation cyclophosphamide, Clinical Sciences, Cardiovascular medicine and haematology
Abstract

The use of post-transplantation cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis in recipients of haploidentical and fully matched transplantations is on the increase. Published studies have reported an increased incidence of cytomegalovirus (CMV) infection with the use of PTCy. Limited data exist on the incidence and outcomes of infection with non-CMV herpesviruses (NCHV) in this setting. The aim of this study was to evaluate the cumulative incidence of NCHV infections and the association of NCHV infections with transplantation-specific outcomes in recipients of haploidentical transplantation with PTCy (HaploCy), matched sibling donor transplantation with PTCy (SibCy), and matched sibling donor transplantation with calcineurin inhibitor-based prophylaxis (SibCNI). We hypothesized that, like CMV infection, HaploCy recipients of also will have a higher risk of NCHV infections. Using the Center for International Blood and Marrow Transplantation Research database, we analyzed 2765 patients (HaploCy, n = 757; SibCNI, n = 1605; SibCy, n = 403) who had undergone their first hematopoietic stem cell transplantation (HCT) between 2012 and 2017 for acute myelogenous leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome. The cumulative incidence of NCHV at 6 months post-NCT was 13.9% (99% confidence interval], 10.8% to 17.3%) in the HaploCy group, 10.7% (99% CI, 7.1% to 15%) in the SibCy group, and 5.7% (99% CI, 4.3% to 7.3%) in the Sib CNI group (P < .001). This was due primarily to a higher frequency of human herpesvirus 6 viremia reported in patients receiving PTCy. The incidence of Epstein-Barr viremia was low in all groups, and no cases of post-transplantation lymphoproliferative disorder were seen in either PTCy group. The incidence of NCHV organ disease was low in all 3 cohorts. The development of NCHV infection was associated with increased treatment-related mortality, particularly in the HaploCy group. There was no association with the development of GVHD, relapse, or disease-free survival. Patients in PTCy cohorts who did not develop NCHV infection had lower rates of cGVHD. This study demonstrates that the use of PTCy is associated with an increased risk of NCHV infection. The development of NCHV infection was associated with increased nonrelapse mortality, especially in the HaploCy group. Prospective trials should consider viral surveillance strategies in conjunction with assessment of immune reconstitution for a better understanding of the clinical relevance of viral reactivation in different HCT settings.

Published
2022

10. Reduced-Intensity Compared to Nonmyeloablative Conditioning in Patients with Non-Hodgkin Lymphoma Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Author

Nath, Karthik, Peterson, Kristen, Brown, Samantha, Devlin, Sean, Rodriguez, Natasia, Barker, Juliet, Giralt, Sergio, Gyurkocza, Boglarka, Jakubowski, Ann, Papadopoulos, Esperanza, Ponce, Doris, Scordo, Michael, Shah, Gunjan, Perales, Miguel-Angel, Sauter, Craig, Lin, Andrew, and Dahi, Parastoo B.

Published
2024
Full Text
View/download PDF

12. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide.

Author

Im, Annie, Rashidi, Armin, Wang, Tao, Hemmer, Michael, MacMillan, Margaret, Pidala, Joseph, Jagasia, Madan, Pavletic, Steven, Majhail, Navneet, Weisdorf, Daniel, Abdel-Azim, Hisham, Agrawal, Vaibhav, Al-Homsi, A, Aljurf, Mahmoud, Askar, Medhat, Auletta, Jeffery, Bashey, Asad, Beitinjaneh, Amer, Bhatt, Vijaya, Byrne, Michael, Cahn, Jean-Yves, Cairo, Mitchell, Castillo, Paul, Cerny, Jan, Chhabra, Saurabh, Choe, Hannah, Ciurea, Stefan, Daly, Andrew, Perez, Miguel, Farhadfar, Nosha, Gadalla, Shahinaz, Gale, Robert, Ganguly, Siddhartha, Gergis, Usama, Hanna, Rabi, Hematti, Peiman, Herzig, Roger, Hildebrandt, Gerhard, Lad, Deepesh, Lee, Catherine, Lehmann, Leslie, Lekakis, Lazaros, Kamble, Rammurti, Kharfan-Dabaja, Mohamed, Khandelwal, Pooja, Martino, Rodrigo, Murthy, Hemant, Nishihori, Taiga, OBrien, Tracey, Olsson, Richard, Patel, Sagar, Perales, Miguel-Angel, Prestidge, Tim, Qayed, Muna, Romee, Rizwan, Schoemans, Hélène, Seo, Sachiko, Sharma, Akshay, Solh, Melhem, Strair, Roger, Teshima, Takanori, Urbano-Ispizua, Alvaro, Van der Poel, Marjolein, Vij, Ravi, Wagner, John, William, Basem, Wirk, Baldeep, Yared, Jean, Spellman, Steve, Arora, Mukta, and Hamilton, Betty

Subjects
Adult, Cyclophosphamide, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Risk Factors, Transplantation Conditioning
Abstract

Post-transplant cyclophosphamide (PTCy) has significantly increased the successful use of haploidentical donors with a relatively low incidence of graft-versus-host disease (GVHD). Given its increasing use, we sought to determine risk factors for GVHD after haploidentical hematopoietic cell transplantation (haplo-HCT) using PTCy. Data from the Center for International Blood and Marrow Transplant Research on adult patients with acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, or chronic myeloid leukemia who underwent PTCy-based haplo-HCT (2013 to 2016) were analyzed and categorized into 4 groups based on myeloablative (MA) or reduced-intensity conditioning (RIC) and bone marrow (BM) or peripheral blood (PB) graft source. In total, 646 patients were identified (MA-BM = 79, MA-PB = 183, RIC-BM = 192, RIC-PB = 192). The incidence of grade 2 to 4 acute GVHD at 6 months was highest in MA-PB (44%), followed by RIC-PB (36%), MA-BM (36%), and RIC-BM (30%) (P = .002). The incidence of chronic GVHD at 1 year was 40%, 34%, 24%, and 20%, respectively (P < .001). In multivariable analysis, there was no impact of stem cell source or conditioning regimen on grade 2 to 4 acute GVHD; however, older donor age (30 to 49 versus

Published
2020

14. Health-Related Values Discussions with Patients Undergoing Allogeneic and Autologous Stem Cell Transplant: Feasibility and Acceptability of an Early Primary Palliative Care Intervention

Author

Cohen, Abigail G., Cho, Christina, Patterson, Emily, Magaldi, Jessica, Doga, Tara, Naputo, Kristine, Alvarez, Kelsey, Giles, Elizabeth, Yang, Grace, Hoque, Afshana, Kramer, Dana, Devlin, Sean, Nemirovsky, David, Rosa, William E., Goldberg, Jessica I., Perales, Miguel-Angel, Epstein, Andrew S., Nelson, Judith E., and Landau, Heather

Published
2025
Full Text
View/download PDF

15. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma

Author

Epperla, Narendranath, Kumar, Ambuj, Abutalib, Syed A., Awan, Farrukh T., Chen, Yi-Bin, Gopal, Ajay K., Holter-Chakrabarty, Jennifer, Kekre, Natasha, Lee, Catherine J., Lekakis, Lazaros, Lin, Yi, Mei, Matthew, Nathan, Sunita, Nastoupil, Loretta, Oluwole, Olalekan, Phillips, Adrienne A., Reid, Erin, Rezvani, Andrew R., Trotman, Judith, Zurko, Joanna, Kharfan-Dabaja, Mohamed A., Sauter, Craig S., Perales, Miguel-Angel, Locke, Frederick L., Carpenter, Paul A., and Hamadani, Mehdi

Published
2023
Full Text
View/download PDF

17. Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas

Author

Riedell, Peter A., Hwang, Wei-Ting, Nastoupil, Loretta J., Pennisi, Martina, McGuirk, Joseph P., Maziarz, Richard T., Bachanova, Veronika, Oluwole, Olalekan O., Brower, Jamie, Flores, Oscar A., Ahmed, Nausheen, Schachter, Levanto, Bharucha, Kharmen, Dholaria, Bhagirathbhai R., Schuster, Stephen J., Perales, Miguel-Angel, Bishop, Michael R., and Porter, David L.

Published
2022
Full Text
View/download PDF

21. Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation

Author

Brunstein, Claudio G, Pasquini, Marcelo C, Kim, Soyoung, Fei, Mingwei, Adekola, Kehinde, Ahmed, Ibrahim, Aljurf, Mahmoud, Agrawal, Vaibhav, Auletta, Jeffrey J, Battiwalla, Minoo, Bejanyan, Nelli, Bubalo, Joseph, Cerny, Jan, Chee, Lynette, Ciurea, Stefan O, Freytes, Cesar, Gadalla, Shahinaz M, Gale, Robert Peter, Ganguly, Siddhartha, Hashmi, Shahrukh K, Hematti, Peiman, Hildebrandt, Gerhard, Holmberg, Leona A, Lahoud, Oscar B, Landau, Heather, Lazarus, Hillard M, de Lima, Marcos, Mathews, Vikram, Maziarz, Richard, Nishihori, Taiga, Norkin, Maxim, Olsson, Richard, Reshef, Ran, Rotz, Seth, Savani, Bipin, Schouten, Harry C, Seo, Sachiko, Wirk, Baldeep M, Yared, Jean, Mineishi, Shin, Rogosheske, John, and Perales, Miguel-Angel

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Hematology, Rare Diseases, Transplantation, Lymphoma, Clinical Research, Cancer, Obesity, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Adult, Aged, Antineoplastic Agents, Drug Dosage Calculations, Female, Hematopoietic Stem Cell Transplantation, Humans, Male, Middle Aged, Mortality, Multiple Myeloma, Recurrence, Transplantation Conditioning, Transplantation, Autologous, Autologous hematopoietic cell transplantation, Conditioning regimen, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

Data are limited on whether to adjust high-dose chemotherapy before autologous hematopoietic cell transplant (autoHCT) in obese patients. This study explores the effects of dose adjustment on the outcomes of obese patients, defined as body mass index (BMI) ≥ 30 kg/m2. Dose adjustment was defined as a reduction in standard dosing ≥20%, based on ideal, reported dosing and actual weights. We included 2 groups of US patients who had received autoHCT between 2008 and 2014. Specifically, we included patients with multiple myeloma (MM, n = 1696) treated with high-dose melphalan and patients with Hodgkin or non-Hodgkin lymphomas (n = 781) who received carmustine, etoposide, cytarabine, and melphalan conditioning. Chemotherapy dose was adjusted in 1324 patients (78%) with MM and 608 patients (78%) with lymphoma. Age, sex, BMI, race, performance score, comorbidity index, and disease features (stage at diagnosis, disease status, and time to transplant) were similar between dose groups. In multivariate analyses for MM, adjusting for melphalan dose and for center effect had no impact on overall survival (P = .894) and treatment-related mortality (TRM) (P = .62), progression (P = .12), and progression-free survival (PFS; P = .178). In multivariate analyses for lymphoma, adjusting chemotherapy doses did not affect survival (P = .176), TRM (P = .802), relapse (P = .633), or PFS (P = .812). No center effect was observed in lymphoma. This study demonstrates that adjusting chemotherapy dose before autoHCT in obese patients with MM and lymphoma does not influence mortality. These results do not support adjusting chemotherapy dose in this population.

Published
2019

22. Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation

Author

Tamari, Roni, Oran, Betul, Hilden, Patrick, Maloy, Molly, Kongtim, Piyanuch, Papadopoulos, Esperanza B, Rondon, Gabriela, Jakubowski, Ann A, Andersson, Borje S, Devlin, Sean M, Ahmed, Sairah, Popat, Uday R, Ponce, Doris, Chen, Julianne, Sauter, Craig, Young, James W, de Lima, Marcos, Perales, Miguel-Angel, O'Reilly, Richard J, Giralt, Sergio A, Champlin, Richard E, and Castro-Malaspina, Hugo

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Rare Diseases, Clinical Research, Transplantation, Stem Cell Research - Nonembryonic - Human, Orphan Drug, Stem Cell Research, Regenerative Medicine, Adult, Aged, Allografts, Antigens, CD34, Chromosome Aberrations, Female, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Lymphocyte Depletion, Male, Middle Aged, Myelodysplastic Syndromes, Recurrence, Risk Assessment, Survival Analysis, Transplantation, Homologous, Treatment Outcome, Myelodysplastic syndrome, Allogeneic transplantation, T cell depletion, Unmodified, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

In this study, we compared transplantation outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) in patients with advanced myelodysplastic syndrome (MDS) who received a CD34+ cell-selected and those who received an unmodified allograft. This analysis initially included 181 patients, 60 who received a CD34+ cell-selected transplant and 121 who received an unmodified transplant. Owing to significant differences in disease characteristics, the analysis was limited to patients with

Published
2018

24. Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy

Author

Kharfan-Dabaja, Mohamed A., Kumar, Ambuj, Ayala, Ernesto, Aljurf, Mahmoud, Nishihori, Taiga, Marsh, Rebecca, Burroughs, Lauri M., Majhail, Navneet, Al-Homsi, A. Samer, Al-Kadhimi, Zaid S., Bar, Merav, Bertaina, Alice, Boelens, Jaap J., Champlin, Richard, Chaudhury, Sonali, DeFilipp, Zachariah, Dholaria, Bhagirathbhai, El-Jawahri, Areej, Fanning, Suzanne, Fraint, Ellen, Gergis, Usama, Giralt, Sergio, Hamilton, Betty K., Hashmi, Shahrukh K., Horn, Biljana, Inamoto, Yoshihiro, Jacobsohn, David A, Jain, Tania, Johnston, Laura, Kanate, Abraham S., Kansagra, Ankit, Kassim, Adetola, Kean, Leslie S., Kitko, Carrie L., Knight-Perry, Jessica, Kurtzberg, Joanne, Liu, Hien, MacMillan, Margaret L., Mahmoudjafari, Zahra, Mielcarek, Marco, Mohty, Mohamad, Nagler, Arnon, Nemecek, Eneida, Olson, Timothy S., Oran, Betul, Perales, Miguel-Angel, Prockop, Susan E., Pulsipher, Michael A., Pusic, Iskra, Riches, Marcie L., Rodriguez, Cesar, Romee, Rizwan, Rondon, Gabriela, Saad, Ayman, Shah, Nina, Shaw, Peter J., Shenoy, Shalini, Sierra, Jorge, Talano, Julie, Verneris, Michael R., Veys, Paul, Wagner, John E., Savani, Bipin N., Hamadani, Mehdi, and Carpenter, Paul A.

Published
2021
Full Text
View/download PDF

25. Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy

Author

Infante, Maria-Stefania, Nemirovsky, David, Devlin, Sean, DeWolf, Susan, Tamari, Roni, Dahi, Parastoo B., Lee, Yeon Joo, Chung, David J., Politikos, Ioannis, Barker, Juliet, Giralt, Sergio A., Babady, N. Esther, Ramanathan, Lakshmi, Papanicolaou, Genovefa A., Seo, Susan, Kamboj, Mini, Perales, Miguel-Angel, and Shah, Gunjan L.

Published
2024
Full Text
View/download PDF

26. Incidence and Impact of Fungal Infections in Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis and Haploidentical Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis

Author

Papanicolaou, Genovefa A., Chen, Min, He, Naya, Martens, Michael J., Kim, Soyoung, Batista, Marjorie V., Bhatt, Neel S., Hematti, Peiman, Hill, Joshua A., Liu, Hongtao, Nathan, Sunita, Seftel, Matthew D., Sharma, Akshay, Waller, Edmund K., Wingard, John R., Young, Jo-Anne H., Dandoy, Christopher E., Perales, Miguel-Angel, Chemaly, Roy F., Riches, Marcie, and Ustun, Celalettin

Published
2024
Full Text
View/download PDF

27. The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy

Author

Garcia-Recio, Marta, Wudhikarn, Kitsada, Pennisi, Martina, Alonso-Trillo, Rosalia, Flynn, Jessica, Shouval, Roni, Afuye, Aishat O., Silverberg, Mari Lynne, Batlevi, Connie W., Dahi, Parastoo, Devlin, Sean, Giralt, Sergio A., Halton, Elizabeth, Ruiz, Josel, Maloy, Molly, Mead, Elena, Palomba, M. Lia, Santomasso, Bianca, Sauter, Craig S., Scordo, Michael, Shah, Gunjan L., and Perales, Miguel-Angel

Published
2021
Full Text
View/download PDF

28. ASTCT Committee on Practice Guidelines Survey on Evaluation & Management of Relapsed Refractory Multiple Myeloma after Failure of Chimeric Antigen Receptor T-Cell Therapy

Author

Hashmi, Hamza, primary, Kumar, Ambuj, additional, Kharfan-Dabaja, Mohamed A., additional, Munshi, Pashna N., additional, Inamoto, Yoshihiro, additional, DeFilipp, Zachariah M., additional, Dholaria, Bhagirathbhai, additional, Jain, Tania, additional, Perales, Miguel-Angel, additional, Carpenter, Paul A., additional, Hamadani, Mehdi, additional, Dhakal, Binod, additional, and Usmani, Saad Z., additional

Published
2024
Full Text
View/download PDF

29. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation

Author

Kharfan-Dabaja, Mohamed A, Kumar, Ambuj, Hamadani, Mehdi, Stilgenbauer, Stephan, Ghia, Paolo, Anasetti, Claudio, Dreger, Peter, Montserrat, Emili, Perales, Miguel-Angel, Alyea, Edwin P, Awan, Farrukh T, Ayala, Ernesto, Barrientos, Jacqueline C, Brown, Jennifer R, Castro, Januario E, Furman, Richard R, Gribben, John, Hill, Brian T, Mohty, Mohamad, Moreno, Carol, O'Brien, Susan, Pavletic, Steven Z, Pinilla-Ibarz, Javier, Reddy, Nishitha M, Sorror, Mohamed, Bredeson, Christopher, Carpenter, Paul, and Savani, Bipin N

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Cancer, Minority Health, Clinical Trials and Supportive Activities, Transplantation, Hematology, Rare Diseases, Lymphoma, Clinical Research, Lymphatic Research, Orphan Drug, Health Disparities, Antineoplastic Agents, Child, Child, Preschool, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Practice Guidelines as Topic, Salvage Therapy, Transplantation Conditioning, Transplantation, Homologous, Chronic lymphocytic leukemia, Allogeneic hematopoietic cell transplantation, BCR inhibitors, BCL-2 inhibitors
Abstract

We sought to establish clinical practice recommendations to redefine the role of allogeneic hematopoietic cell transplantation (allo-HCT) for patients with chronic lymphocytic leukemia (CLL) in an era of highly active targeted therapies. We performed a systematic review to identify prospective randomized controlled trials comparing allo-HCT against novel therapies for treatment of CLL at various disease stages. In the absence of such data, we invited physicians with expertise in allo-HCT and/or CLL to participate in developing these recommendations. We followed the Grading of Recommendations Assessment, Development and Evaluation methodology. For standard-risk CLL we recommend allo-HCT in the absence of response or if there is evidence of disease progression after B cell receptor (BCR) inhibitors. For high-risk CLL an allo-HCT is recommended after failing 2 lines of therapy and showing an objective response to BCR inhibitors or to a clinical trial. It is also recommended for patients who fail to show an objective response or progress after BCR inhibitors and receive BCL-2 inhibitors, regardless of whether an objective response is achieved. For Richter transformation, we recommend allo-HCT upon demonstration of an objective response to anthracycline-based chemotherapy. A reduced-intensity conditioning regimen is recommended whenever indicated. These recommendations highlight the rapidly changing treatment landscape of CLL. Newer therapies have disrupted prior paradigms, and allo-HCT is now relegated to later stages of relapsed or refractory CLL.

Published
2016

31. Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma

Author

Ahmed, Nausheen, Wesson, William, Mushtaq, Muhammad Umair, Porter, David L., Nasta, Sunita D., Brower, Jamie, Bachanova, Veronika, Hu, Marie, Nastoupil, Loretta J., Oluwole, Olalekan O., Patel, Vivek G., Oliai, Caspian, Riedell, Peter A., Bishop, Michael R., Shah, Gunjan L., Perales, Miguel-Angel, Schachter, Levanto, Maziarz, Richard T., and McGuirk, Joseph P.

Published
2023
Full Text
View/download PDF

32. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome

Author

Hines, Melissa R., Knight, Tristan E., McNerney, Kevin O., Leick, Mark B., Jain, Tania, Ahmed, Sairah, Frigault, Matthew J., Hill, Joshua A., Jain, Michael D., Johnson, William T., Lin, Yi, Mahadeo, Kris M., Maron, Gabriela M., Marsh, Rebecca A., Neelapu, Sattva S., Nikiforow, Sarah, Ombrello, Amanda K., Shah, Nirav N., Talleur, Aimee C., Turicek, David, Vatsayan, Anant, Wong, Sandy W., Maus, Marcela V., Komanduri, Krishna V., Berliner, Nancy, Henter, Jan-Inge, Perales, Miguel-Angel, Frey, Noelle V., Teachey, David T., Frank, Matthew J., and Shah, Nirali N.

Published
2023
Full Text
View/download PDF

33. Success of an International Learning Health Care System in Hematopoietic Cell Transplantation: The American Society of Blood and Marrow Transplantation Clinical Case Forum

Author

Barba, Pere, Burns, Linda J, Litzow, Mark R, Juckett, Mark B, Komanduri, Krishna V, Lee, Stephanie J, Devlin, Sean M, Costa, Luciano J, Khan, Shakila, King, Andrea, Klein, Andreas, Krishnan, Amrita, Malone, Adriana, Mir, Muhammad A, Moravec, Carina, Selby, George, Roy, Vivek, Cochran, Melissa, Stricherz, Melisa K, Westmoreland, Michael D, Perales, Miguel-Angel, Wood, William A, and Education, American Society for Blood and Marrow Transplantation Committee on

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Cancer, Rare Diseases, Pediatric, Hematology, Transplantation, Allografts, Autografts, Hematologic Neoplasms, Hematopoietic Stem Cell Transplantation, Humans, Societies, Medical, United States, Allogeneic hematopoietic stem cell transplantation, Autologous stem cell transplantation, Case discussions, Clinical Sciences, Immunology, Cardiovascular medicine and haematology
Abstract

The American Society for Blood and Marrow Transplantation (ASBMT) Clinical Case Forum (CCF) was launched in 2014 as an online secure tool to enhance interaction and communication among hematopoietic cell transplantation (HCT) professionals worldwide through the discussion of challenging clinical care issues. After 14 months, we reviewed clinical and demographical data of cases posted in the CCF from January 29, 2014 to March 18, 2015. A total of 137 cases were posted during the study period. Ninety-two cases (67%) were allogeneic HCT, 29 (21%) were autologous HCT, and in 16 (12%), the type of transplantation (autologous versus allogeneic) was still under consideration. The diseases most frequently discussed included non-Hodgkin lymphoma (NHL; n = 30, 22%), acute myeloid leukemia (n = 23, 17%), and multiple myeloma (MM; n = 20, 15%). When compared with the US transplantation activity reported by the US Department of Health and Human Services, NHL and acute lymphoblastic leukemia cases were over-represented in the CCF, whereas MM was under-represented (P < .001). A total of 259 topics were addressed in the CCF with a median of 2 topics/case (range, 1 to 6). Particularly common topics included whether transplantation was indicated (n = 57, 41%), conditioning regimen choice (n = 44, 32%), and post-HCT complications after day 100 (n = 43, 31%). The ASBMT CCF is a successful tool for collaborative discussion of complex cases in the HCT community worldwide and may allow identification of areas of controversy or unmet need from clinical, educational and research perspectives.

Published
2016

34. Real-World Experience Study of Belumosudil in Steroid-Refractory Chronic Graft-Versus-Host Disease (cGVHD) Demonstrated High Treatment Response without Significant Toxicities

Author

Raju, Gagan, primary, Walji, Moneeza, additional, Nemirovsky, David, additional, Devlin, Sean M., additional, Goldstein, Ilan, additional, Singh, Amandeep, additional, Susman, Pamela, additional, Rodriguez, Natasia T., additional, Perales, Miguel-Angel, additional, and Ponce, Doris M., additional

Published
2024
Full Text
View/download PDF

35. Identification of Pre-Treatment Clinical Risk Factors Predictive of Inferior Survival and Increased Risk of Treatment Failure in CD19 Chimeric Antigen Receptor T Cell Recipients with Large B Cell Lymphoma.

Author

Geethakumari, Praveen Ramakrishnan, primary, Wudhikarn, Kitsada, additional, Jain, Michael D., additional, Vallurupalli, Anusha, additional, Kim, Soyoung, additional, Oloyede, Temitope, additional, Awan, Farrukh T, additional, Mirza, Abu-Sayeef, additional, Bachanova, Veronika, additional, Badar, Talha, additional, Barba, Pere, additional, Beitinjaneh, Prof. Amer, additional, Cashen, Amanda, additional, Dholaria, Dr. Bhagirathbhai, additional, Elsawy, Mahmoud, additional, Farooq, Umar, additional, Foglesong, Jessica, additional, Ganguly, Siddhartha MD, additional, Greenbaum, Uri, additional, Hashmi, Hamza, additional, Hill, LaQuisa Chimere, additional, Jain, Dr. Tania, additional, Kebriaei, Partow, additional, Kittai, Adam S., additional, Locke, Frederick L., additional, Lulla, Premal D., additional, Mead, Elena, additional, McGuirk, Joseph P, additional, Mussetti, Alberto, additional, Nishihori, Taiga, additional, Olson, Amanda L., additional, Pennisi, Martina, additional, Perales, Miguel-Angel, additional, Riedell, Peter A., additional, Saber, Wael, additional, Shouval, Roni, additional, Shpall, Elizabeth J., additional, Sorror, Mohamed L., additional, Strouse, Christopher Sun, additional, Turtle, Cameron J., additional, Pasquini, Marcelo C., additional, Moskop, Amy, additional, and Ahmed, Sairah, additional

Published
2024
Full Text
View/download PDF

36. Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) As a Biomarker of Acute Kidney Injury Requiring Dialysis (AKI-D) in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT): Results from the Blood and Marrow Transplant Clinical Trials Network 1202 Study

Author

Bhasin-Chhabra, Bhavna, primary, Wang, Tao, additional, Levine, John E, additional, Shenoy, Shalini, additional, Perales, Miguel-Angel, additional, Bashey, Asad, additional, Raff, Hershel, additional, and Saber, Wael, additional

Published
2024
Full Text
View/download PDF

37. Phase 2 Trial of Ruxolitinib Cream for Chronic Cutaneous GvHD

Author

Markova, Alina, primary, Papadopoulos, Esperanza B., additional, Dusza, Stephen, additional, Rotemberg, Veronica, additional, Ostojic, Jelena, additional, Ai, Rizi, additional, Maier, Tara, additional, Lacouture, Mario E., additional, Tamari, Roni, additional, Gyurkocza, Boglarka, additional, Shaffer, Brian C., additional, Scordo, Michael, additional, Perales, Miguel-Angel, additional, Harris, Andrew C., additional, and Ponce, Doris M., additional

Published
2024
Full Text
View/download PDF

38. Sars-Cov-2 Vaccination in the First Year after Hematopoietic Cell Transplant or Chimeric Antigen Receptor T Cell Therapy: A CIBMTR and BMT CTN Study

Author

Hill, Joshua A., primary, Martens, Michael J., additional, Young, Jo-Anne H., additional, Bhavsar, Kavita, additional, Kou, Jianqun, additional, Chen, Min, additional, Lee, Lik Wee, additional, Baluch, Aliyah, additional, Dhodapkar, Madhav Vishnu, additional, Nakamura, Ryotaro, additional, Peyton, Kristin, additional, Shahid, Zainab, additional, Armistead, Paul M., additional, Westervelt, Peter, additional, McCarty, John M., additional, McGuirk, Joseph P, additional, Hamadani, Mehdi, additional, DeWolf, Susan, additional, Hosszu, Kinga, additional, Sharon, Elad, additional, Spahn, Ashley, additional, Toor, Dr. Amir A., additional, Waldvogel, Stephanie, additional, Greenberger, Lee M., additional, Auletta, Dr. Jeffery J., additional, Horowitz, Mary M., additional, Riches, Marcie L., additional, and Perales, Miguel-Angel, additional

Published
2024
Full Text
View/download PDF

39. Regulatory T Cell Reconstitution Is Associated with Acute Graft-Versus-Host Disease in Pediatric and Young Adult Hematopoietic Cell Transplant Recipients

Author

Hosszu, Kinga, primary, McAvoy, Devin, additional, Garcia-Rosa, Moises, additional, White, Charlie, additional, Thomsen, Matthew, additional, Ntrivalas, Evangelos, additional, Klein, Elizabeth, additional, Mauguen, Audrey, additional, Curran, Kevin J., additional, Cancio, Maria I., additional, Scaradavou, Andromachi, additional, Kung, Andrew L., additional, Oved, Joseph H., additional, Perales, Miguel-Angel, additional, Harris, Andrew C., additional, and Boelens, Jaap Jan, additional

Published
2024
Full Text
View/download PDF

40. Standard of Care Electronic Patient Reported Outcomes Using Promis-29 after Hematopoietic Stem Cell Transplant and Chimeric Antigen Receptor T Cell Therapy.

Author

Korsos, Victoria, primary, Lobaugh, Stephanie M., additional, Sukhu, Ranjit, additional, Devlin, Sean M., additional, Atkinson, Thomas, additional, Kemeny, Elizabeth, additional, Stetson, Peter, additional, Perales, Miguel-Angel, additional, Giralt, Sergio A., additional, Scordo, Michael, additional, and Shah, Gunjan L., additional

Published
2024
Full Text
View/download PDF

41. A Focused Multidisciplinary Telehealth Clinic Increased Patient Access and Significantly Reduced Distress in Patients with Gvhd.

Author

Harris, Andrew C., primary, Markova, Alina, additional, Devlin, Sean M., additional, Susman, Pamela, additional, Singh, Amandeep, additional, Myers, Michelle, additional, Brown, Soni, additional, Grasso, Christine, additional, Estilo, Cherry L., additional, Yom, SaeHee, additional, Custodio, Christian M., additional, Ibanez, Katarzyna, additional, Syrkin, Grigory, additional, Perales, Miguel-Angel, additional, and Ponce, Doris M., additional

Published
2024
Full Text
View/download PDF

42. Impact of Tocilizumab on CAR-T Cells Outcome and Toxicity: Results from a Large B Cell Lymphoma Cohort

Author

Cassanello, Giulio, primary, Devlin, Sean M., additional, Landego, Ivan, additional, de Abia, Alejandro Luna, additional, Corona, Magdalena, additional, Rivas-Delgado, Alfredo, additional, Luttwak, Efrat, additional, Parascondola, Allison, additional, Saldia, Amethyst, additional, Dahi, Parastoo B., additional, Lin, Dr. Richard J., additional, Palomba, M. Lia, additional, Park, Jae H., additional, Salles, Gilles, additional, Perales, Miguel-Angel, additional, Scordo, Michael, additional, Shouval, Roni, additional, and Shah, Gunjan, additional

Published
2024
Full Text
View/download PDF

43. Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT).

Author

DiPersio, John F., primary, Cooper, Brenda, additional, Suh, Hyung C., additional, Koura, Divya, additional, Bernard, Léa, additional, Shah, Nirali N., additional, Walter, Roland B., additional, Perales, Miguel-Angel, additional, Mapara, Markus Y., additional, Tamari, Roni, additional, Loken, Michael, additional, Breitschwerdt, Kyle, additional, Nath, Sritama, additional, Raffel, Glen D, additional, and Koehne, Guenther, additional

Published
2024
Full Text
View/download PDF

44. Defining the Optimal Post-CART Monitoring Period in Recipients of Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel: A Cell Therapy Consortium Study

Author

Wesson, William, primary, Riedell, Peter A., additional, Porter, David L., additional, Lutfi, Forat, additional, Bachanova, Veronika, additional, Nastoupil, Loretta J., additional, Maziarz, Richard T., additional, DeJarnette, Shaun, additional, Brower, Jamie, additional, Shah, Gunjan L., additional, Chen, Andy I., additional, Oluwole, Olalekan O., additional, Schuster, Stephen J., additional, Perales, Miguel-Angel, additional, Bishop, Michael R., additional, McGuirk, Joseph P, additional, and Ahmed, Nausheen, additional

Published
2024
Full Text
View/download PDF

45. Budesonide Use for Grade 2 Gastrointestinal Graft-Versus-Host Disease after Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis

Author

Cook, Melinda, primary, Vadakkel, Grashma, additional, Chinapen, Ms. Stephanie, additional, Perales, Miguel-Angel, additional, Tamari, Roni, additional, Papadopoulos, Esperanza B., additional, Gyurkocza, Boglarka, additional, Shaffer, Brian C., additional, Ponce, Doris M., additional, and Lin, Andrew, additional

Published
2024
Full Text
View/download PDF

46. Digital Droplet PCR Based Monitoring of CAR-T Cell Expansion in Lymphoma Patients: Impact on Treatment Outcome

Author

Cassanello, Giulio, primary, Borsu, Laetitia, additional, Arcila, Maria E., additional, Yao, JinJuan, additional, Momeni-Boroujeni, Amir, additional, Ewalt, Mark D, additional, Patel, Utsav, additional, Chan, Roger, additional, Gray, Brandon, additional, de Abia, Alejandro Luna, additional, Corona, Magdalena, additional, Luttwak, Efrat, additional, Rivas-Delgado, Alfredo, additional, Landego, Ivan, additional, Parascondola, Allison, additional, Saldia, Amethyst, additional, Flynn, Jessica, additional, Devlin, Sean M., additional, Dahi, Parastoo B., additional, Lin, Dr. Richard J., additional, Palomba, M. Lia, additional, Scordo, Michael, additional, Shouval, Roni, additional, Salles, Gilles, additional, Perales, Miguel-Angel, additional, and Shah, Gunjan, additional

Published
2024
Full Text
View/download PDF

47. Calcineurin Inhibitor-Free Graft-Versus-Host Disease (GVHD) Prophylaxis in Hematopoietic Cell Transplantation (HCT) with Myeloablative Conditioning Regimens (MAC) and HLA-Matched Donors: Long Term Follow up of BMT CTN 1301 Progress II Trial

Author

Pasquini, Marcelo C., primary, Soiffer, Robert, additional, Logan, Brent, additional, Kaur, Manmeet, additional, Devine, Steven M., additional, Geller, Nancy, additional, Giralt, Sergio A., additional, Heslop, Helen E., additional, Horowitz, Mary M., additional, Litzow, Mark R., additional, Mendizabal, Adam, additional, Muffly, Lori S, additional, Nemecek, Eneida, additional, O'Donnell, Lynn C., additional, Schetelig, Johannes, additional, Shune, Leyla, additional, Solomon, Scott R., additional, Vasu, Sumithira, additional, Ho, Dr. Vincent T., additional, Perales, Miguel-Angel, additional, and Luznik, Leo, additional

Published
2024
Full Text
View/download PDF

48. Phase I Study of Bendamustine and Melphalan Conditioning Followed By Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma and B-Cell Lymphoma in Elderly Patients

Author

Raju, Gagan, primary, Shah, Gunjan L., additional, Lobaugh, Stephanie M., additional, Devlin, Sean M., additional, Vadakkel, Grashma, additional, Eng, Stephen William, additional, Lin, Andrew, additional, Saldia, Amethyst, additional, Donach, Martin, additional, Engstler, Danielle, additional, Aremu, Yetunde, additional, Lahoud, Oscar B., additional, Hamlin, Paul, additional, Scordo, Michael, additional, Perales, Miguel-Angel, additional, Sauter, Craig S, additional, Moskowitz, Craig H., additional, Lin, Dr. Richard J., additional, Giralt, Sergio A., additional, and Dahi, Parastoo B., additional

Published
2024
Full Text
View/download PDF

49. High Progression-Free Survival with Low Relapse Rates after Double-Unit Cord Blood Transplantation in Patients with High-Risk AML

Author

Politikos, Ioannis, primary, Brown, Samantha, additional, Fingrut, Warren Benjamin, additional, Chinapen, Ms. Stephanie, additional, Quach, Sean, additional, Dahi, Parastoo B., additional, Gyurkocza, Boglarka, additional, Jakubowski, Ann A., additional, Papadopoulos, Esperanza B., additional, Perales, Miguel-Angel, additional, Ponce, Doris M., additional, Tamari, Roni, additional, Scaradavou, Andromachi, additional, and Barker, Juliet, additional

Published
2024
Full Text
View/download PDF

50. Early CD4 and B Cell Immune Reconstitution As Predictors of Outcomes in T Cell Depleted Allogeneic Hematopoietic Cell Transplantation

Author

Lucas, Alexandre G. Troullioud, primary, Scordo, Michael, additional, Lakkaraja, Madhavi, additional, Cho, Christina, additional, Jakubowski, Ann A., additional, Papadopoulos, Esperanza B., additional, Tamari, Roni, additional, Curran, Kevin J., additional, O'Reilly, Richard J., additional, Scaradavou, Andromachi, additional, Gyurkocza, Boglarka, additional, Giralt, Sergio A., additional, Perales, Miguel-Angel, additional, and Boelens, Jaap Jan, additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results